(19)

(11)

EP 4 247 364 A1

(12)

(43) Date of publication: 27.09.2023 Bulletin 2023/39 (21) Application number: 21895549.0 (22) Date of filing: 18.11.2021

(51) International Patent Classification (IPC):  A61K 31/416(2006.01) A61K 31/445(2006.01) A61K 31/551(2006.01) A61K 31/435(2006.01) A61K 31/47(2006.01) A61K 47/26(2006.01) (52) Cooperative Patent Classification (CPC): A61K 31/496; A61K 9/006; A61K 9/2018; A61K 9/2063; A61K 9/2013 (86) International application number: PCT/US2021/059801 (87) International publication number: WO 2022/109077 (27.05.2022 Gazette 2022/21)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 19.11.2020 US 202063115789 P 17.12.2020 US 202063126550 P (71) Applicant: Pfizer Ireland Pharmaceuticals Ringaskiddy Cork (IE)	(72) Inventors: CONWAY, Charles M. New Haven, Connecticut 06510 (US) DUBOWCHIK, Gene M. New Haven, Connecticut 06510 (US) KUMAR, Rajesh New Haven, Connecticut 06510 (US) (74) Representative: Pfizer  European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 75668 Paris Cedex 14 (FR)